FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPI	ROVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	e 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

	pe Response													
Name and Address of Reporting Person* De La Rosa Abel			2. Issuer Name and Ticker or Trading Symbol Virios Therapeutics, Inc. [VIRI]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director 10% Owner					
(Last) (First) (Middle) C/O VIRIOS THERAPEUTICS, INC., 44 MILTON AVENUE			· ~ `	3. Date of Earliest Transaction (Month/Day/Year) 06/23/2022						Officer (gi	ve title below)	Oth	er (specify below	v)
(Street) ALPHARETTA, GA 30009			4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(Cit	y)	(State)	(Zip)	Table I - Non-Derivative Securities Acq			ies Acquir	uired, Disposed of, or Beneficially Owned						
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	any	med on Date, if Day/Year	Code (Inst	•	4. Securities A (A) or Dispose (Instr. 3, 4 and	d of (D) O 5) T	5. Amount of Securities B Owned Following Reporte Transaction(s) (Instr. 3 and 4)		ed	Ownership Form:	7. Nature of Indirect Beneficial Ownership
							ode V	Amount (A)	or	,		or Indirect (I) (Instr. 4)		
								ned in this f		collection ot required				474 (9-02)
							contai form o	ned in this folioned in	orm are no rrently val	ot required llid OMB co	to respon	d unless the		474 (3-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if	4. Transact	5. Notion of Derir Secu Acqu (A) of Disp of (E) (Inst	mber vative rities ired rosed) . 3, 4,	form of the contact o	ned in this folisplays a cure cosed of, or Boonvertible securically and Date	orm are no rrently val eneficially (urities)	ot required did OMB co Owned and Amount rlying es	8. Price of	d unless the	f 10. Ownersh Form of Derivativ Security: Direct (E or Indirec	11. Nature of Indire Benefici Ownersh (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transact	5. Notion of Derice Security Acquired (A) of Disp	arrant amber vative rities ired rosed)	contained form of the	ned in this filisplays a cu	eneficially (urities) 7. Title a of Under Securitie	ot required did OMB co Owned and Amount rlying es	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(f 10. Ownersh Form of Derivativ Security: Direct (E or Indirects) (I)	11. Nature of Indire Benefici Ownersh (Instr. 4)

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
De La Rosa Abel C/O VIRIOS THERAPEUTICS, INC. 44 MILTON AVENUE ALPHARETTA, GA 30009	X				

Signatures

/s/ Greg Duncan, Attorney-in-Fact	06/30/2022
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a)
- (1) The stock option will vest 100% on June 23, 2023, one year following the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.